Rani Therapeutics Holdings, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Talat Imran
- Full Time Employees
- 71
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 2051 Ringwood Avenue San Jose CA United States of America 95131
- IPO Date
- Jul 30, 2021
- CIK
- 0001856725
- Website
- ranitherapeutics.com
- Similar Companies
- Business
- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI) operates as a clinical-stage biotherapeutics company that develops innovative technologies to enable the oral administration of biologics and drugs as a needle-free alternative to subcutaneous or intravenous injections for patients with chronic conditions. The company offers the proprietary RaniPill capsule platform, a drug-agnostic oral delivery system designed to accommodate a wide range of drug substances including antibodies, proteins, peptides, oligonucleotides, and other large molecules; this includes the RaniPill GO for payloads up to 3 mg with demonstrated high bioavailability comparable to injections, and the RaniPill HC under preclinical development for higher payloads up to 20 mg. Its pipeline features multiple product candidates leveraging the RaniPill technology, such as RT-101 (octreotide) in Phase 1 for acromegaly and neuroendocrine tumors; RT-102 (parathyroid hormone analog) in Phase 1 for osteoporosis; RT-105 (anti-TNF-alpha antibody) in preclinical stage for psoriatic arthritis; RT-109 (human growth hormone) for growth hormone deficiency; RT-110 (parathyroid hormone) for hypoparathyroidism; RT-111 (ustekinumab biosimilar) for inflammatory conditions; RT-114 and RT-116 for obesity treatments; as well as programs targeting GLP-1 agonists for type 2 diabetes and basal insulin for diabetes management. Founded in 2012 and headquartered in San Jose, California, Rani Therapeutics focuses on the biotechnology sector within healthcare, primarily targeting patients requiring biologic therapies for endocrine, immunology, metabolic, and rare diseases across the United States and global markets through partnerships. In recent developments, the company entered a landmark collaboration agreement in October 2025 with Chugai Pharmaceutical worth up to $1.085 billion, including a $10 million upfront payment, up to $75 million in technology transfer and development milestones, up to $100 million in sales milestones, and single-digit royalties on one initial drug target with options for five additional targets; concurrently, Rani closed an oversubscribed $60.3 million private placement financing led by Samsara BioCapital with participation from RA Capital Management, Anomaly Special Situations Funds, Invus, and founder Mir Imran to fund operations into 2028.
Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing
Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates
Rani Therapeutics Appoints Nicholas Maestas as Chief Financial Officer
Rani Therapeutics Holdings, Inc. Announces Pricing of $20.0 Million Registered Direct Offering of Class A Common Stock Priced At-The-Market Under Nasdaq Rules
Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition
Rani Therapeutics to Participate in the H.C. Wainwright Annual BioConnect Investor Conference
Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy
Rani Therapeutics Holdings, Inc. (RANI) Q4 2025 Earnings Call Transcript
Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update
Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization
Milestone Pharmaceuticals (NASDAQ:MIST) versus Rani Therapeutics (NASDAQ:RANI) Head to Head Review
Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Average Recommendation of “Moderate Buy” from Brokerages
Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer
Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen
Rani Therapeutics (NASDAQ:RANI) Stock Price Down 2.2% – What’s Next?
Rani Therapeutics to Participate in the Evercore Healthcare Conference
Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update
Rani Therapeutics Sees Unusually Large Options Volume (NASDAQ:RANI)